Poniard Pharmaceuticals Top Management
PARDDelisted Stock | USD 0.01 0.00 0.00% |
Poniard Pharmaceuticals employs about 7 people. The company is managed by 2 executives with a total tenure of roughly 17 years, averaging almost 8.0 years of service per executive, having 3.5 employees per reported executive. Evaluation of Poniard Pharmaceuticals' management performance can provide insight into the firm performance.
Paul Abrams Insider Ex Officer |
Robert Caspari Insider Ex Officer |
Poniard |
Poniard Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.4603) % which means that it has lost $0.4603 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1037) %, meaning that it created substantial loss on money invested by shareholders. Poniard Pharmaceuticals' management efficiency ratios could be used to measure how well Poniard Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Poniard Pharmaceuticals Workforce Comparison
Poniard Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 6,242. Poniard Pharmaceuticals adds roughly 7.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Poniard Pharmaceuticals Notable Stakeholders
A Poniard Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Poniard Pharmaceuticals often face trade-offs trying to please all of them. Poniard Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Poniard Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Paul Abrams | Ex Officer | Profile | |
Robert Caspari | Ex Officer | Profile |
About Poniard Pharmaceuticals Management Performance
The success or failure of an entity such as Poniard Pharmaceuticals often depends on how effective the management is. Poniard Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Poniard management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Poniard management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington. PONIARD PHARMACEUT operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs 7 people.
Please note, the presentation of Poniard Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Poniard Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Poniard Pharmaceuticals' management manipulating its earnings.
Poniard Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Poniard Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Poniard Pharmaceuticals within its industry.Poniard Pharmaceuticals Manpower Efficiency
Return on Poniard Pharmaceuticals Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 4.3M | |
Net Loss Per Executive | 15M | |
Working Capital Per Employee | 514.4K | |
Working Capital Per Executive | 1.8M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Poniard Pink Sheet
If you are still planning to invest in Poniard Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Poniard Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |